Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Pulmonary Embolism 1

Interventions

Epoetin Alfa 27Darbepoetin alfa 13Cytarabine 9Dalteparin 8Rivaroxaban 7Daunorubicin 7apixaban 6Etoposide 6Methotrexate 5Idarubicin 5Heparin, Low-Molecular-Weight 5Cyclophosphamide 5emicizumab 4Tinzaparin 4Thioguanine 4Mitoxantrone 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Enoxaparin 4pegfilgrastim 3hetrombopag 3epoetin beta 3Saline Solution 3Radiotherapy 3Hydrocortisone 3Erythropoietin 3Dexamethasone 3Aspirin 3Asparaginase 3telapristone acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Dabigatran × Classical hematology × Clear all
NCT03240120 2019-04-17

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

The University of Hong Kong

Phase 3 Unknown
99 enrolled
Classical hematology

Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡